Application of genetic screening information to the management of medullary thyroid carcinoma and multiple endocrine neoplasia type 2.
Application of RET proto-oncogene mutation analysis to the clinical management of MEN 2 and FMTC has simplified and enhanced the power of earlier used screening and treatment efforts for hereditary MTC. The approaches outlined herein are cost-effective, have improved diagnostic accuracy, and hold the promise of improved cure rates for this neoplasm. Further studies to elucidate the mechanism by which these activating mutations cause transformation may lead to other strategies for prevention or treatment of this neoplasm.
Section of Endocrinology, Division of Surgery, University of Texas, Houston, USA.
N
N
Wohllk
G J
GJ
Cote
D B
DB
Evans
H
H
Goepfert
N G
NG
Ordonez
R F
RF
Gagel
D001483:Base Sequence; D018276:Carcinoma, Medullary / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D005820:Genetic Testing; D006801:Humans; D008969:Molecular Sequence Data; D018813:Multiple Endocrine Neoplasia Type 2a / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D009154:Mutation; D010375:Pedigree; D000090063:Proto-Oncogene Mas; D011519:Proto-Oncogenes; D013964:Thyroid Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy